Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: atreya r. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. Among authors: atreya r. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Treatment Strategies in Inflammatory Bowel Diseases.
Stallmach A, Atreya R, Grunert PC, Stallhofer J, de Laffolie J, Schmidt C. Stallmach A, et al. Among authors: atreya r. Dtsch Arztebl Int. 2023 Nov 10;120(45):768-778. doi: 10.3238/arztebl.m2023.0142. Dtsch Arztebl Int. 2023. PMID: 37408514 Free PMC article. Review.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009.
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Kucharzik T, et al. Among authors: atreya r. Z Gastroenterol. 2023 Aug;61(8):1046-1134. doi: 10.1055/a-2060-0935. Epub 2023 Aug 14. Z Gastroenterol. 2023. PMID: 37579791 Free article. German. No abstract available.
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R, Germer CT, Grunert PC, Helwig U, Horisberger K, Herrlinger K, Kienle P, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators. Sturm A, et al. Among authors: atreya r. Z Gastroenterol. 2024 Aug;62(8):1229-1318. doi: 10.1055/a-2309-6123. Epub 2024 Aug 7. Z Gastroenterol. 2024. PMID: 39111333 Free article. German. No abstract available.
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.
Fischer S, Donhauser M, Cohnen S, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, Rath T, Wilfer A, Sologub L, Krebs S, Dörje F, Nagore D, Meyer S, Neurath MF, Atreya R. Fischer S, et al. Among authors: atreya r. Therap Adv Gastroenterol. 2024 Nov 30;17:17562848241301887. doi: 10.1177/17562848241301887. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39619829 Free PMC article.
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G. Atreya R, et al. J Crohns Colitis. 2024 Nov 1:jjae164. doi: 10.1093/ecco-jcc/jjae164. Online ahead of print. J Crohns Colitis. 2024. PMID: 39485390
278 results